Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430677 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT00430677: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00430677 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 423 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430677, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.
Primary Outcome
Confirmed at 2 consecutive visits. CRR defined as meeting all of 5 criteria. Renal function (RF): (Glomerular filtration rate \[GFR\] calculated using Modification of Diet in Renal Diseases equation equation) Calculated function abnormal at screening visit - return of renal function to greater than or equal to 90% of function at approximately 6 months prior to onset of the current episode of lupus nephritis. Calculated function normal at screening visit - estimated renal function 90% or greater
Interventions
- DRUG Abatacept
- DRUG Mycophenolate mofetil (MMF)
- DRUG Corticosteroids (prednisone or prednisolone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Why NCT00430677 stopped before completion
NCT00430677 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher).
The record links to 0 conditions, and to 3 interventions - of which Abatacept is the first listed.
NCT00430677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00430677 about?
NCT00430677 is a clinical study titled "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis". The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.
What is the current status of trial NCT00430677?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2007-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00430677?
The interventions under investigation include: Abatacept (DRUG), Mycophenolate mofetil (MMF) (DRUG), Corticosteroids (prednisone or prednisolone) (DRUG).
Who is sponsoring clinical trial NCT00430677?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00430677's enrollment target sits among peer trials
423 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia